Advice
In the absence of a submission from the holder of the marketing authorisation
bosentan (Tracleer) is not recommended for use within NHSScotland to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- bosentan 62.5mg 125mg film coated tablets (Tracleer)
- SMC ID:
- 485/08
- Indication:
- to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease
- Pharmaceutical company
- Actelion Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 June 2008